TTX-333 is under clinical development by Temple Therapeutics and currently in Phase II for Scar. According to GlobalData, Phase II drugs for Scar does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TTX-333 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTX-333 overview
Evitar is under development for the prevention of postoperative adhesions or fibrosis or scar tissue. It is a first in class drug. The drug candidate is a peptide comprised of endogenous amino acids, formulated in an aqueous form. It is administered through intraperitoneal route.
Temple Therapeutics overview
Temple Therapeutics is a biotechnology company involved in the research and production of therapy treatments for cancer related diseases, orthopedics,and endometriosis patients. The company is headquartered in Geleen, Limburg, The Netherlands.
For a complete picture of TTX-333’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
